Independent educationNo sales. No dosing. Sources on every brief.

Exact claim · Version 1 · Reviewed 2026-07-24

“Retatrutide is FDA-approved.”

A verdict on this wording and scope, not a universal grade for Retatrutide.

01 · Verdict

Misleading

It remains investigational. Positive trial results and sponsor announcements are not FDA marketing approval.

Evidence basis
Regulatory or product record
Scope
United States regulatory status as reviewed July 24, 2026.
Category
Approval and status

02 · Primary record

Check the attached evidence

Editorial review
Internal editorial review recorded
Responsible editor
Anthony Treviso · Founder and responsible editor
Clinical-review boundary
Not independently medically reviewed.